- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.09. | Major trial of Roche Alzheimer's drug kicks off in Europe | ||
| 04.09. | Merck rare tumour drug Ezmekly backed for NHS use | ||
| 04.09. | Pig to human kidney transplantation hits a new milestone | ||
| 04.09. | Viral disease-carrying Aedes mosquito 'breeding in London' | ||
| 04.09. | AbbVie's cancer TCE etentamig hits the mark in myeloma | ||
| 04.09. | Ionis claims first approval for Alexander disease therapy | ||
| 03.09. | Ultragenyx to slash costs after Angelman trial failure | ||
| 03.09. | Hutchmed rises on $1.3bn KRAS licensing deal with GSK | ||
| 03.09. | Netcompany claims NHS contract to help digitise screening | ||
| 03.09. | Akeso's ivonescimab extends survival in PD-L1+ lung cancer | ||
| 03.09. | Boehringer signs AI drug discovery deal with Owkin | ||
| 02.09. | FDA issues warning letters to five unapproved GLP-1 websites | ||
| 02.09. | PMV cues up filing for first p53-directed cancer therapy | ||
| 02.09. | MHRA launches first regional tech 'sandbox' in Manchester | ||
| 02.09. | US puts $125m into personalised RNA therapy production | ||
| 01.09. | Enhertu OK ends 10-year EU gap in frontline breast cancer | ||
| 01.09. | Roche taps Simcere for autoimmune trispecific for $1.53bn | ||
| 01.09. | Novartis sets sights on new oral MS drug after phase 3 wins | ||
| 01.09. | GSK pushes 'next-generation' mRNA flu shot into phase 3 | ||
| 01.09. | Novartis halts CAR-T trials after patient deaths | ||
| 01.09. | White House signs pricing deals with nine more pharmas | ||
| 31.08. | ESC26: Can Arrowhead pierce Ionis' triglyceride armour? | ||
| 31.08. | ESC26: AZ's relaxin agonist shows promise in heart failure | ||
| 31.08. | FDA clears Takeda, Protagonist's first-in-class PV drug | ||
| 31.08. | ESC26: Cytokinetics' big data reveal for Myqorzo impresses |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.